Skip to content
Screener

Nuvation Bio NUVB Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Immunome logo
ImmunomeIMNM
-$73.46M-69.2%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$43.6M+32.1%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$189.52M-200%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.32B+202%
Enterprise value$2.07B+259%
P/S13.6×-39.8×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Net loss per share attributable to common stockholders, basic and diluted$(0.18)$(0.17)$(0.17)$(0.33)
Weighted average common shares outstanding, basic and diluted348,770340,746348,055339,685
Comprehensive loss:
Net loss$(62,840)$(59,007)$(57,443)$(112,243)
Other comprehensive loss, net of taxes:
Currency translation adjustment(471)(646)(739)(182)
Change in unrealized loss on available-for-sale securities(463)(225)(1,685)(718)
Comprehensive loss$(63,774)$(59,878)$(59,867)$(113,143)

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's comprehensive income (loss), net of tax, attributable to parent?
Nuvation Bio (NUVB) reported comprehensive income (loss), net of tax, attributable to parent of -$63.77M in Q2 2026.
How has Nuvation Bio's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Nuvation Bio's comprehensive income (loss), net of tax, attributable to parent decreased by 6.5% year-over-year, from -$59.88M to -$63.77M.
What is the long-term trend for Nuvation Bio's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Nuvation Bio's comprehensive income (loss), net of tax, attributable to parent has grown at a 23.0% compound annual growth rate (CAGR), from -$89.59M to -$205.39M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, including net income and other items such as foreign currency translation adjustments and unrealized gains or losses on securities. It provides a more holistic view of the company's financial performance beyond the traditional income statement. Investors use this to evaluate the overall impact of market and economic factors on the company's total shareholder value.

Ask your AI about Nuvation Bio's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude